Dr Reddy’s Laboratories Ltd, India’s second-largest drug maker, has tied up with Australian pharmaceutical company Hatchtech Pty Ltd to commercialise head lice topical lotion Xeglyze in a deal valued at around $198 million (Rs. 1,306 crore) based on regulatory and sales milestones.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
